EXTON, Pa., Sept. 3, 2015 (GLOBE NEWSWIRE) -- Fibrocell Science, Inc., (NASDAQ:FCSC), an autologous cell and gene therapy company focused on developing first-in-class treatments for rare and serious skin and connective tissue diseases with high unmet medical needs, today announced that David Pernock, Chairman and Chief Executive Officer, will present at the Wells Fargo 2015 Healthcare Conference at 2:55 pm EDT on Wednesday, September 9 in Boston. He will also present at the Ladenburg Thalmann 2015 Healthcare Conference at 1:00 pm EDT on Tuesday, September 29 in New York City.
The presentations will be webcast live under the Investors & Media section of Fibrocell's website at fibrocell.com/investors/events-and-presentations, and will be archived there. Please visit the company's website several minutes prior to the start of each broadcast to ensure adequate time for any software download that may be necessary.
About Fibrocell Science, Inc.
Fibrocell Science, Inc. (NASDAQ:FCSC) is an autologous cell and gene therapy company focused on developing first-in-class treatments for rare and serious skin and connective tissue diseases with high unmet medical needs. Fibrocell's most advanced product candidate, azficel-T, uses its proprietary autologous fibroblast technology and is in a Phase II clinical trial for the treatment of chronic dysphonia resulting from vocal cord scarring. In collaboration with Intrexon Corporation (NYSE:XON), a leader in synthetic biology, Fibrocell is also developing gene therapies for skin diseases using gene-modified autologous fibroblasts. Fibrocell has submitted an IND application to the FDA for FCX-007, its lead orphan gene-therapy product candidate, for the treatment of recessive dystrophic epidermolysis bullosa (RDEB). Fibrocell is in pre-clinical development of FCX-013, its second gene-therapy product candidate, for the treatment of linear scleroderma. For more information, visit www.fibrocell.com.
CONTACT: Investor & Media Relations Contact: Karen Casey Fibrocell Science, Inc. +1 (484) 713-6133 email@example.comSource:Fibrocell Science, Inc.